The other shoe finally drops for device dealmaking
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
Teneo’s heavy chain success keeps on delivering
Yesterday’s takeout of Teneotwo came amid notable big pharma interest in the geeky science behind heavy chain-only antibodies.
The trigger for a Seagen buyout
Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.
Epizyme accepts reality
Dire market conditions combine with a loan overhang and investor desertion to force Epizyme's hand in a low-ball takeout.
Biotech smells the coffee
A couple of small M&A deals this week shows more developers capitulating to the new reality.
To buy or build blockbusters?
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Galapagos starts spending Gilead’s cash
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
